Deltagen Announces First Drug Development Target From Its Research Pipeline; DT011M is a Specific and Key Player in Insulin Secretion.

Publication: PR Newswire

Bookmark this article Print this article Link to this article Email this article Digg It! Add to del.icio.us RSS

COPYRIGHT 2002 PR Newswire Association LLC

REDWOOD CITY, Calif. -- Deltagen, Inc. , announced today the identification of DT011M, a key insulin-mediating drug target, for the potential treatment of obesity and related diseases, such as diabetes. Deltagen has plans to initiate a chemical screening program and compound development efforts during 2002.

"Current drugs for diabetes seek to manage blood glucose level and do not address the underlying disorder. We believe that our target mediates insulin secretion from the pancreas after meals causing a direct decrease in fat production and storage in the body as well as mediating insulin sensitivity," said Stephen J. Peroutka, M.D., Ph.D., vice president of clinical research at Deltagen. "The ability to objectively and systematically analyze multiple molecular targets within a single biochemical pathway...

Read the full article for free courtesy of your local library.